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Abstract
Recent US Supreme Court decisions have invalidated patent claims on isolated genomic DNA, and testing methods that
applied medical correlations using conventional techniques. As a consequence, US genetic testing laboratories have a
relatively low risk of infringing patents on naturally occurring DNA or methods for detecting genomic variants. In Europe,
however, such claims remain patentable, and European laboratories risk infringing them. We report the results from a survey
that collected data on the impact of patents on European genetic testing laboratories. The results indicate that the proportion
of European laboratories that have refrained from providing associated testing services owing to patent protection has
increased over the last decade (up from 7% in 2008 to 15% in 2017), and that the non-proﬁt sector was particularly strongly
affected (up from 4% in 2008 to 14% in 2017). We renew calls for more readily available legal support to help public sector
laboratories deal with patent issues, but we do not recommend aligning European law with US law at present. Watchful
monitoring is also recommended to ensure that patents do not become a greater hindrance for clinical genetic testing
laboratories.
Introduction
The patentability of genetic inventions and discoveries has
been socially, legally and ethically controversial for decades
[1, 2]. In the 1990s, surges in the number of patents
claiming gene-related inventions [3]—especially isolated
gDNA—prompted investigations around the world to assess
whether patents had adversely impacted genetic testing
services [4–9]. In the United States, some studies showed
negative impacts. For example, in a 2001 survey, Cho et al.
[10] found that 53% of US laboratories had decided not to
develop or perform a test (either for research or clinical
purposes) due to a patent. Furthermore, in 2010, a US
government report found that patents had generally limited
the availability of services rather than promoted them [11].
Other US studies reached different conclusions, including
that patents rarely hamper academic and commercial
research [12, 13], and that there is positive correlation
between DNA-based patents and investment in R&D [14].
The impediments reported in these surveys, as well as
others, motivated the American Civil Liberties Union and
the Association of Molecular Pathology to challenge
patenting of isolated DNA in the United States [15]. The
Supreme Court responded sympathetically. In Association
for Molecular Pathology v. Myriad Genetics Inc [16]
(Myriad), the Court invalidated patent claims to isolated
gDNA on the grounds that they were not ‘markedly dif-
ferent’ to what exists in nature. One year earlier in unrelated
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litigation, the Court in Mayo Collaborative Services v.
Prometheus Laboratories Inc (Mayo) held that the mere
application of natural phenomena using conventional tech-
niques was not patentable either. The patent in Mayo con-
cerned a method for more precisely dosing a drug based on
observing the patient’s drug-metabolite levels. However,
courts have since applied the case to invalidate a variety of
patents relevant to methods for diagnosing conditions based
on observing genetic characteristics, including methods for
non-invasive prenatal testing (NIPT) [17] and for identify-
ing whether a patient has a disease-linked variant [18]. That
said, some key aspects of genetic testing still remain eligible
for US patent protection; including laboratory-engineered
DNA (e.g., complementary DNA, and recombinant DNA)
[19] and sequencing techniques [20].
The patent law changes in the United States have not
(yet) been mirrored in European patent law, and are cur-
rently the focus of intense enquiry and discussion in the
United States [21–23]. Should we implement similar law
reform in Europe? What impact are gene-related patents
having on European clinical genetic laboratories? Is the
impact as signiﬁcant as it was in the United States prior to
the US Supreme Court decisions? These questions were the
motivation for this study.
Background
European patent law provides relatively broad protection for
gene-related patents. The European Directive on the Pro-
tection of Biotechnological Inventions (98/44/EC) states that
isolated DNA sequences shall be patentable in European
Member States. The European Patent Convention is inter-
preted in the same way by the European Patent Ofﬁce. The
inherent patentability of isolated DNA sequences was con-
ﬁrmed in the European BRCA litigation [24]. The patents
were reduced substantially in scope but not rejected for
being unpatentable subject matter [25, 26]. Genetic diag-
nostic methods are also patent eligible in Europe, even when
the techniques implementing the methods are conventional.
For example, a UK court recently held that, in contrast to the
US case, the European patent for NIPT is valid [27]; and the
apex patent court in Germany, the Bundesgerichtshof,
recently conﬁrmed the validity of patent claims on both the
isolated human FLT3 gene and methods for evaluating
whether a patient has a certain variant in FLT3 [28, 29].
Although the European Patent Convention excludes meth-
ods of diagnosis on the human body, this exclusion has been
interpreted narrowly and does not exclude in vitro diagnostic
methods such as methods of genetic testing based on blood,
cells or saliva samples [30, 31].
It is ~ 10 years since European laboratories were last
surveyed about the impact of gene-related patents. At the
time, patents were not having as much of an impact on
European laboratories as they were in the United States.
Gaisser et al. [5] found in 2008 that only 7% of European
laboratories reported discontinuing a test due to a patent.
This and other results led the authors to conclude that there
was no patent ‘menace in Europe—yet’. Stressing the time-
limited nature of their conclusion, however, the authors
suggested that patents might affect services adversely in the
future, especially as new technology might increase both the
number of people and genes tested. A recent review of the
impact of patents on medical practice in the UK concluded
that ‘neither current nor future medical practices appear to
be impinged by gene patents’ [32], but this review was not
based on any new data.
In the decade since Gaisser et al.’s survey, there have
been signiﬁcant developments. Accordingly, a fresh sur-
vey is essential if we are to understand the present-day
impact of gene-related patents on European clinical
genetic laboratories. For instance, the power and scale of
sequencing and testing techniques have rapidly advanced
since 2008—especially with the uptake of whole genome/
exome sequencing. Governments around the world have
cumulatively committed vast sums to genomic medicine
programmes, with a primary aim of stratifying patients
based on genetic traits to achieve more accurate diagnosis,
prognosis and treatment [33]. With these technological
and ﬁnancial inputs, the Western European clinical
molecular genetic testing ‘industry’ has grown markedly
—a 2015 commercial report found that the industry has
been growing at over 10% since 2013 and predicted it to
be worth US$3.08 billion by 2020 [34]. At the same time,
it is possible that the US cases have inﬂuenced companies
to shift the focus of patent enforcement actions from the
US to Europe, where they, arguably, stand better chances
of success [35].
This survey-based study seeks a present-day under-
standing of the scale of patent-based impacts on clinical
genetic testing services. In order that one can see change
over time in Europe, as well as inter-regional comparison
(with the US and Australia), this study follows earlier
surveys in covering: laboratories’ awareness of patent
rights; whether patentees have enforced their rights; how
laboratories have responded to enforcement efforts; whe-
ther laboratories have obtained patent licenses either
bundled with commercial testing kits or through con-
tractual licenses; whether laboratories have outsourced
tests in an attempt to avoid patent infringement; whether
patents have restricted laboratories’ R&D; and whether
laboratories have refrained from performing a test due to a
patent. These questions do not deﬁnitively answer whether
patients are able to access speciﬁc clinical genetic services.
However, they do indicate the nature and scale of patent-
based impacts on laboratories.
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Methods
Survey instrument and design
The survey was based on those used in Gaisser et al.’s 2008
European survey and a similar Australian study by Nicol
et al. [6] in 2012. A pilot survey was tested by designated
persons in the research team, and two independent persons
respectively specialising in genetics policy for the UK civil
service and a clinical genetics. Participation was voluntary
and estimated to take 20 minutes. Laboratories were not
required to answer every question. The survey was provided
in English only. The survey referred to gene-related impacts
of patents on clinical genetic testing laboratories. This
language deliberately left open the possibility of labora-
tories raising issues with patents on nucleic acid bio-
markers, methods of detection and diagnosis, and platform
technologies. There were several reasons for taking this
wide approach rather than, for example, limiting the study
to biomarker patents: laboratories are affected by patents
relating to biomarkers, methods, and platforms; US legal
developments have affected all such patents; and there is no
strict demarcation in the sense that platform technologies
can involve a variety of nucleic acid markers and methods
of clinical diagnosis.
Distribution
The survey was distributed via two channels. First, on 8
May 2017, it was emailed to 1068 European molecular
genetics laboratories listed on a database provided by
Orpha.net (we cleaned and updated some contacts in the
database but no large changes were made). Second, on 5
June 2017, the survey was sent to the 561 European
member laboratories of the European Molecular Genetics
Quality Network (EMQN). Two email reminders were sent
via each channel. Owing to possible cross-posting on the
two channels, respondents were asked to ensure their
laboratory had not already completed the survey.
Gaisser et al. used the EuroGentest laboratory network to
distribute their survey in 2008. The list of genetic labora-
tories in that network was incorporated into Orpha.net in
2008. The reason for using a second channel in this study
(EMQN) was that 101 emails sent to addresses listed on the
Orpha.net database bounced, raising the possibility that
many more emails were not received, likely owing to staff
turnover.
The number of laboratories contacted successfully via the
two channels was estimated by a cohort of follow-up tele-
phone calls after the survey closed on 6 July 2017. Through
the telephone calls, we estimated that the survey was received
by 806 laboratories (see Supplementary Material). By
comparison, the 2008 European survey was emailed to 289
laboratories.
Two hundred and four laboratories that provide human
clinical molecular genetic testing started the survey, and
158 completed it; meaning that 25% began it and 20%
completed it. By comparison, the 2008 European survey
had 83 responses, and the 2001 US survey had 132 com-
pleted responses. The 2008 European survey is the only
study to have assessed response bias; it found no response
bias in terms of laboratory size, nationality or reason for not
responding.
Statistical analysis
The number of complete responses (158) makes this the
largest study on this topic. It was large enough to compare
the results of this survey with Gaisser et al.’s 2008 Eur-
opean survey with 90% conﬁdence intervals (CIs). These
calculations are located in the Supplementary Material. The
sample size was too small for robust statistical analysis
between sub-groups in the sample. For example, we could
not say with conﬁdence or statistical signiﬁcance that for-
proﬁt laboratories (one sub-group) were more likely to
discontinue clinical genetic tests due to a patent than pub-
licly funded genetic laboratories (another sub-group).
Nevertheless, we follow the earlier survey studies and report
associations between sub-groups based on descriptive
statistics.
Results and discussion
Laboratories’ characteristics
The number of laboratories emailed in this study (~ 806)
compared with the number emailed in the 2008 study (289)
suggests that there has been a substantial growth in the
European clinical genetic sector. In part, this increase might
be driven by the increased visibility of laboratories, which
in turn is due to better web-based networking. The results
also show that 141 (75%) laboratories are part of non-proﬁt
organisations, and 47 (25%) are part of for-proﬁt organi-
sations. In contrast, the 2008 survey found that only 7% of
laboratories were from for-proﬁt organisations, an 18%
difference from the 2018 ﬁndings (90% CI= ± 8%). This
increase in the for-proﬁt sector ﬁts the data reported above
about the ﬁnancial growth in the industry. Laboratories,
regardless of whether they identiﬁed as proﬁt or non-proﬁt,
were also asked to specify what type of organisation they
were from. Government-funded hospitals, universities, and
small- or medium-size companies together constituted 76%
of all respondents (Table 1).
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Geographically, 29 (15%) laboratories werre based in
Italy, 24 (12%) in Germany, 23 (12%) in Spain, 19 (10%) in
the UK, 17 (9%) in France, and another 78 (41%) were from
20 different countries.
The size of laboratories was gauged by asking how many
test reports they issued per year: 11 (9%) issued < 100; 39
(21%) issued 100–499; 23 (12%) issued 500–999; 77 (41%)
issued 1000–5000; and 39 (21%) issued > 5000. The
majority of responding laboratories were thus relatively
large.
The same question was asked in the 2008 survey.
Comparatively, the proportion of laboratories in the three
middle size categories are similar, but the proportion of the
smallest and largest laboratories are noticeably different.
From 2008 to 2017, the proportion of laboratories providing
< 100 has decreased by 5% (90% CI= ± 7%), whereas the
proportion providing > 5000 tests has increased by 10%
(90% CI= ± 9%) (Supplementary Material).
Laboratories also responded to questions about types of
testing, whether laboratory staff have been involved in
patenting, and respondents’ roles in the laboratories
(Supplementary Material).
Awareness of patent rights
Laboratories were asked whether they conducted tests using
patented genes or methods of diagnosis: 70 (37%) stated
they did, whereas 63 (34%) said they did not, and 55 (29%)
did not know. Ten of these 70 laboratories were from Italy,
9 each from Germany and Spain, 7 each from France and
the UK, with an additional 27 laboratories distributed across
13 further countries.
The 2008 European survey asked a slightly different
question: whether laboratories conducted tests on patented
genes. In response, 18 (22%) laboratories reported they did,
45 (54%) said they did not, and 20 (24%) did not know.
Patents on genes often include methods for analysing the
gene of interest, thus we suspect these two questions have
been interpreted the same way in both surveys. Assuming
this is correct, 2008–2017 saw a 16% (90% CI= ± 10%)
increase in laboratories knowingly conducting patented
tests. What is driving this increase is currently unclear but
may be a combination of factors. An obvious factor is that a
higher proportion of laboratories are now contacted about
potential infringement (see below), but laboratories may
simply be more aware of patent rights owing to media
coverage of recent European litigation. A greater proportion
of laboratories might be infringing patented tests, but this
possibility cannot be drawn convincingly from the data.
Enforcement of patents
Laboratories were asked whether they had been contacted
about alleged patent infringement: 21 (13%) stated that they
had been, 126 (76%) said they had not been, and 18 (11%)
did not know if they had been. This question was not asked
in the 2008 European survey, however, a 2010 interview-
based study of UK laboratories found that patentees had not
enforced any patents against the laboratories interviewed
[36], indicating contact from patent owners has increased
over time.
This interpretation is reinforced by the following ﬁnding.
In the present study, 20 of the 21 laboratories that had been
contacted disclosed their country: six were from the UK;
three from Germany; two each from Belgium, Switzerland,
Austria and Sweden; and one each from Italy, France and
the Netherlands. This means that 100% (2/2) of the Swed-
ish, 40% (2/5) of the Belgian and 32% (6/19) of the UK
laboratories in this survey had been contacted about
infringement by patent holders.
Laboratories were asked to list the tests affected by the
allegation of patent infringement. Nine laboratories reported
one test each, whereas another four reported two tests.
Totalled together: 11 listed FLT3, 3 NIPT, 1 RAD51C, 1 Ig/
TCR clonality testing and 1 JAK2.
We observed positive associations between laboratories
that have been contacted about alleged patent infringement
and those that: (a) are larger in size; (b) offer tests on cancer
Table 1 Organisations to which
laboratories belong
Type of organisation For proﬁt Non proﬁt Total for organsiation type % of all laboratories
Blood bank 0 2 2 1%
Private hospital 3 0 3 2%
Company–large 6 0 6 3%
Public research institute 0 10 10 5%
Non-proﬁt/non-state hospital 0 12 12 6%
Private research institute 5 7 12 6%
Company–SME 27 2 29 16%
University 4 43 47 25%
Government-funded hospital 1 65 66 35%
Total 46 141 187 100%
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or blood disorders; (c) knowingly undertake tests on
patented genes and methods; (d) are from for-proﬁt orga-
nisations; and (e) have higher levels of IP support.
(Supplementary Material).
Although we observed a positive association between
laboratories contacted by patent holders and laboratories
that knowingly use patented genes or methods, only 14 of
the laboratories that knowingly used gene-related patents
had been contacted regarding infringement (25% of the
laboratories that answered both questions). This suggests
that the majority of laboratories learn they are using
patented genes and methods from sources other than
infringement allegations. The 2010 interview-based UK
study concluded that laboratories deliberately ignored the
possibility of patent enforcement [38]. The results of this
survey suggest that now, at least for a small number of tests,
fewer laboratories ignore the possibility of enforcement and
more now choose to respect IP rights. It is not clear what is
driving this change in behaviour, but informal clinician
feedback suggests that it is due to the risk of enforcement
increasing [37]. That is, news of parties enforcing patents
has spread throughout the sector.
Responses to patent protection
Laboratories have several options when faced with a
patented genes or methods of diagnosis they do not have
authority to conduct. They can (1) choose to not offer the
test; and (2) refrain from R&D involving the patented gene
or method. Alternatively, licences to use patented genes or
methods of diagnosis can be secured in one of two typical
ways: (3) by purchasing a commercially supplied testing kit
(where the cost of a patent license is bundled into the kit
price); and/or (4) by negotiating a patent license to perform
the testing in-house, including as a laboratory developed
test (LDT) or ‘homebrew’ test (an “unbundled license”). It
is less well known that: (5) outsourcing a genetic test can be
a way to avoid patent infringement, particularly if the test is
outsourced to a country where there is no relevant patent
protection [38, 39].
Each of these ﬁve responses can have implications for
service quality. Obviously, not offering a genetic test limits
the availability of the test; less obviously, it limits oppor-
tunities for second opinions. Outsourcing can result in
longer test turn-around times. A commercial kit may be
more expensive for payors and, potentially, offer a restricted
analysis to the patient compared with an LDT. On the other
hand, a kit may have met more rigorous regulatory checks
than the LDT option, but this depends on the regulatory
environment [40]. A decision to refrain from R&D makes
improvements less likely.
Prior to our survey, it was not known to what extent
genetic laboratories were responding to patents that might
interfere with their services. The questions were designed to
identify whether patent issues underpinned these choices
and the relative importance of other issues.
Genetic test services blocked by patents
Laboratories were asked whether they had chosen not to
perform a test owing to a patent (i.e., refrained from
performing a test). Twenty-six (15%) laboratories
reported they had refrained from performing a test owing
to a patent, whereas 113 (67%) said patents had not
stopped them from performing a test and 30 (18%) did
not know if a patent had stopped them from performing a
test (Figure 1a). Of the 26 laboratories to refrain from
offering a test, 18 (69%) were from non-proﬁt organisa-
tions and 8 (31%) from for-proﬁt organisations. Geo-
graphically, ﬁve laboratories that chose not to provide a
test were located in Germany, four each in the UK and
Switzerland, three in France, and a further eight labora-
tories in nine different countries. This means that 36% of
Swiss laboratories and 21% of UK laboratories that
Fig. 1 A Laboratories’ responses
to whether they had refrained
from performing test (2008 vs
2017). Compared with the 2008
European survey, the percentage
of laboratories that have
refrained from performing a test
has increased from 7 to 15%
(“do not know” responses are
omitted). B Percentage of non-
proﬁt laboratories that chose not
to provide a test (2008 vs 2017).
Compared with the 2008
European survey, the percentage
of non-proﬁt laboratories that
chose not to provide a test has
increased from 4 to 14%
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responded to this survey chose not to perform a test
owing to a patent.
Compared with previous surveys, this result indicates
that an increased number of European laboratories have
refrained from performing a test owing to a patent. The
2008 European survey found that 7% of laboratories had
refrained from performing a test, meaning there has been an
8% increase in almost a decade (90% CI= ± 7%). The
2008 study also found that only 4% of laboratories from
non-proﬁt organisations had refrained from offering a test,
whereas this survey has found this proportion has more than
tripled to 14%, a 10% increase (90% CI= ± 7) (Fig. 1b).
The current percentage of affected European laboratories
across the sector (15%) is also greater than that found in
Australia in 2012 (7%), but markedly lower than the per-
centages found in the United States in 2001 (25% ceased
performing a test after receiving an infringement notiﬁca-
tion; and 53% did not develop or perform a test for clinical
or research purposes owing to a patent.
The laboratories that chose not to perform a test were
asked to specify the test in question, and 14 laboratories
responded with one test each: 6 listed FLT3; 4 NIPT; 1
ABCB1; 1 RAD51C/CHK2; and 1 chromosome X linkage
analysis. An additional laboratory stated they chose not to
provide a test for predisposition to cancer but did not pro-
vide any speciﬁc details.
Previous surveys listed different tests that were not
offered owing to a patent (for example, BRCA1/2,
TCF7L2). Two reasons for the list changing is that patents
will have expired in the intervening time, and more recently
patented tests will have been developed. This shows that the
expiry of patents does not solve the general issue of patents
impacting genetic laboratories.
Laboratories that chose not to provide a test owing to a
patent were asked to rate ﬁve reasons why a patent might be
inﬂuential, including among others that the patent involved
unreasonable costs, risks of patent enforcement and turn-
around time due to insistence that the test be performed
elsewhere (e.g., in the patent owner’s laboratory). Respon-
dents rated these reasons on a scale from being irrelevant
through to being the deciding factor. All six laboratories
that chose not to provide FLT3 testing answered this
question, but only three of the four laboratories that chose
not to provide NIPT answered. The most prominent reasons
to not provide FLT3 were: unreasonable licensing price and
risk of patent enforcement. The most prominent reasons to
not provide NIPT were: unreasonable licensing cost, the
inability to obtain a reagent from a third party, and risk of
patent enforcement (see Supplementary Material).
A positive association was found between laboratories
that chose not to provide a test owing to a patent and those
that: (a) were from for-proﬁt organisations; (b) had higher
levels of IP support; (c) received allegations of patent
infringement; and (d) conducted tests on patented genes or
methods (Supplementary Material).
Although we observed a positive association between
laboratories that chose not to provide a test owing to a
patent and those that had been contacted about alleged
infringement, 11 chose not to offer a test without being
contacted (48% of the laboratories to answer both ques-
tions). Thus, this result indicates that almost half of the
laboratories that chose not to offer a test owing to a patent
decided to do so without infringement being alleged. This
reinforces points made above about European laboratories
being more aware of patents than in previous studies.
Patents and R&D
One hundred and six (65%) laboratories reported that they
conducted R&D, whereas 35 (21%) said they did not and 23
(14%) said they did not know. Research-active laboratories
were then asked if they intended to apply (as an inventor)
for a patent in the future: 20 (19%) reported they did; 36
(34%) said probably not; 20 (19%) said no and 29 (28%)
said they had not thought about it.
Laboratories that did conduct R&D were also asked if
they had decided not to conduct R&D involving a genetic
test owing to a patent: seven (7%) said they had decided not
to conduct R&D owing to a patent, whereas 83 (80%) said
patents had not affected their R&D decisions and 14 (13%)
did not know. Two laboratories reported the genetic test
where they had refrained from R&D. One cited fragile X
syndrome; and another cited the ‘Roche diagnostic panel for
oncology’.
In comparison, the 2008 European survey found a similar
number of research-active laboratories (70%), and a similar
number that had decided not to conduct R&D on a test
owing to a patent (4%). As previously noted, Cho et al. [10]
found that 53% of US laboratories had decided not to
develop or perform a test for either clinical or research
purposes due to patent (it is unclear from this combined
percentage precisely what percentage stopped R&D).
Kits and bundled licenses
One hundred and sixty-four (88%) laboratories reported that
they used commercially-supplied kits, and 23 (12%) said
they did not. Laboratories that used kits were then asked if a
patent license (or royalty) was included in the purchase
price of their kit: 20 (14%) reported that one was included,
12 (8%) said no license was included, and 115 (78%)
laboratories said they did not know (see Supplemen-
tary Material for which kits were reported as including a
license). By contrast, the 2008 European survey found that
4% of laboratories purchased kits that included patent
licenses, indicating an increase of 10% (90% CI= ± 7%). A
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positive association exists between laboratories that pur-
chase kits with bundled licenses and those that undertake
tests on patented genes or methods of diagnosis.
Laboratories that used kits were then presented with
seven reasons why a laboratory might choose a kit in
preference to an LDT and asked to rate each of them on a
six-point Likert scale (from very important to very unim-
portant, including not relevant). We created weighted
average ratings for each reason (Table 2). These averages
were calculated by creating a weighted count for each
reason, and then dividing this count by the number of
respondents that rated the reason. The ratings were
weighted as follows: very important= 2; important= 1;
neutral= 0; unimportant=−1; very unimportant=−2;
and not relevant= 0.
Saving time and increased accuracy/conﬁdence were the
most inﬂuential reasons to choose a kit instead of per-
forming an LDT, both have weighted average weights of
1.1 (important). In contrast, risk of patent enforcement was
the least important reason, with a weighted average rating of
.1 (neutral or not applicable). This reason did, however,
obtain a wide range of responses: 7 laboratories (5%) rated
it as very important, 32 (23%) as important, 56 (39%) as a
neutral consideration, 14 (10%) as unimportant, 6 (4%) as
very unimportant (8%) and 27 (19%) as not a relevant
consideration. No similar question was asked in the 2008
European survey.
It is clear from these ﬁndings that the vast majority of
laboratories are choosing to use kits for reasons other than
as a response to potential patent infringement. Nevertheless,
the ﬁnding that 14% of laboratories use a kit that includes a
license and 28% of laboratories said that patent enforcement
is an important or very important consideration when
choosing to use kits shows that many laboratories are
conscious of the issue and a non-trivial proportion act on it.
A positive association exists between laboratories from
for-proﬁt organisations and those that said patent
enforcement was a very important or an important con-
sideration (Supplementary Material).
Unbundled licenses
Laboratories were then asked if they paid a license fee other
than one included in the purchase price of a kit. Nine (5%)
laboratories reported they did, whereas 121 (72%) said they
did not, and 39 (23%) did not know if they did. Three of the
nine that paid a license had been contacted by patent holders
regarding patent infringement. It is possible that this contact
motivated these three laboratories to take out a license and
pay license fees but the results show that it is more common
(as seen in six out of the nine laboratories) to pay license
fees outside of the purchase price of kits without being
contacted about alleged patent infringement. This is a fur-
ther evidence that not all labs are ignoring patents.
Four laboratories speciﬁed which tests they paid licenses
for: two listed NIPT and the other two listed next generation
sequencing (NGS). As NGS kits typically include a license
in the purchase price of the kit, it is unclear whether the
laboratories who mentioned it answered the question cor-
rectly. One of the laboratories that licensed NIPT was a
large, for-proﬁt company in Switzerland, and the other was
part of a large, government-funded hospital in the UK. Both
said that the license fee was unreasonable. One laboratory
listed the price at $70 USD(~€60) per test.
The 5% of laboratories paying a stand-alone license fee
is an increase over the 2008 European survey in which only
1% responded positively to this question [10], a difference
of 4% (90% CI= ± 4%). This result, however, is lower than
the 13% found in the Australian survey and the 27% in the
United States survey (although, the US survey did not
distinguish between license fees bundled with kits or not).
Respondents were also asked whether they performed
any centrally-licensed tests (e.g. tests in which a govern-
ment negotiated licenses for state hospitals). One hundred
and twelve laboratories (66%) reported that they did not
perform any centrally licensed test, whereas 55 (32%) said
they did not know if they did.
Patents and outsourcing
Laboratories were asked whether they outsourced testing
and their reasons for doing so. Eighty-seven laboratories
(52%) stated they did outsource tests, whereas 79 (48%)
said they did not. Laboratories that did outsource were then
presented with six reasons why a laboratory might choose to
outsource and were asked to rate each of them on a six-point
Likert scale. Table 3 shows a weighted average rating for
each reason (created using the method in Table 2).
The most inﬂuential reasons to outsource were: low test
volume, saves time and difﬁculty in performing test. In
Table 2 Reasons to use a kit instead of an LDT
Reasons n Weighted average
rating
Saves time 145 1.1
Increased accuracy/conﬁdence 147 1.1
Saves money 143 0.7
Minimises the need for validation per
EU/national regulations
147 0.7
Difﬁculty in performing an LDT 147 0.7
Not having to outsource 144 0.6
Risk of patent enforcement 142 0.1
Weighted average ratings showing that the risk of patent enforcement
does not generally inﬂuence laboratories to use kits
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contrast, risk of patent infringement was rated as the least
inﬂuential reason: two laboratories (3%) selected it as very
important and 12 (15%) as an important consideration.
These 14 laboratories were asked which tests they out-
sourced. Only three laboratories answered, listing one test
each: FLT3; ABCB1; and ‘CGH [comparative genomic
hybridisation] array NGS’.
IP support
In the 2008 European survey, 37% of responding labora-
tories said that they did not have access to sufﬁcient support
to deal with patent-related issues, whereas 30% said they
did have enough support (and 30% did not know). In the
2018 survey, more ﬁne-grained answers to this question
were sought and provided: 15% said that they never had
support and 32% said they sometimes did not have support,
whereas 5% said that always had sufﬁcient support and 17%
said they did most of the time (n= 156) (31% did not
know). Although the questions were phrased differently, the
results suggest that the availability of support has not
improved.
Legal policy implications
The central question motivating this study was whether
Europe should follow the path of the US and restrict the
patentability of gene-related patents. The legal mechanics
for such a change are not straightforward [41], and evidence
in support would need to be strong. Relevant evidence
includes whether gene-related patents are having a negative
impact on European clinical genetic laboratories.
Results from this study conﬁrm that, to a degree, patents
are posing challenges for European laboratories, and that
the impact has increased since 2008. Most notably, the
proportion of laboratories across the sector that have
refrained from performing a test due to a patent has
approximately doubled and the number of laboratories from
non-proﬁt organisations that have refrained has more than
tripled (albeit both from a low baseline number) (Box 1).
Furthermore, these impacts are observed across Europe (13
countries in our study), and are most pronounced in coun-
tries with large populations and high per-capita healthcare
expenditure—i.e., the more-lucrative markets for commer-
cial interests. The impact is also magniﬁed by the marked
increase in the number of clinical genetic testing labora-
tories. Where patents are having an impact, they are
potentially affecting a greater number of organisations.
Five further results demonstrating the increased impacts
or importance of patents on clinical genetic laboratories
include: 16% more laboratories now knowingly conduct
tests on patented genes or methods than a decade ago; 10%
more now purchase kits that have licenses bundled into the
purchase price; 28% of laboratories think the threat of
patent enforcement is an important or very important reason
to choose to use a commercial kit; almost one in ﬁve
laboratories regard patents as an important or very impor-
tant reason to outsource genetic tests; and a signiﬁcant
number of laboratories in speciﬁc countries have been
contacted about patent infringement, namely: 100% (2/2) of
the Swedish, 40% (2/5) of the Belgian and 32%
(6/19) of the UK laboratories that participated in this
survey.
These results, however, must be put in context. For
example: 76% of laboratories have not been contacted
regarding patent infringement; the conﬁdence intervals on
some differences between the 2008 results and this survey
are quite wide; and only 5% of laboratories have negotiated
stand-alone patent licenses. In addition, 31% do not know if
they have IP support, only 7% have changed research
interests owing to a patent, and 29% do not know if they
conduct tests on patented genes or methods. These results
indicate that for a signiﬁcant proportion of laboratories,
Table 3 Reasons to outsource tests
Reasons n Weighted average rating
Low test volume 84 1.08
Saves time 83 0.94
Difﬁculty in performing test 86 0.91
Saves money 84 0.85
Increased conﬁdence in the test 83 0.64
Risk of patent infringement 81 −0.01
Weighted average ratings showing that the risk of patent enforcement
does not generally inﬂuence laboratories to outsource tests
Box 1 Key results at a glance
Compared with a decade ago:
● Laboratories that have refrained from offering a test
due to a patent increased from 7 to 15%.
● Non-proﬁt laboratories that refrained from offering
test due to a patent increased from 4 to 14%.
● Laboratories that knowingly conducted tests on
patented genes or methods increased from 22 to 37%
But impacts are still not wide spread. In 2017:
● 76% of laboratories have not been contacted about
infringement.
● 7% have changed research interests due to a patent.
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patent issues are not a primary concern. Furthermore, if one
were to separate NIPT from the analysis (for example, on
the grounds it is a platform technology and therefore war-
rants a different approach in patent law), the impact of
patents on laboratories is even smaller.
The negative impacts for laboratories outlined above are
not in and of themselves negative for patients and the
healthcare system. For instance, the mere fact that a patent
leads a laboratory to discontinue a test is a negative impact
on that lab, but it is not necessarily negative for a healthcare
system or patients. The impact on patients depends on
several factors, for example: is there a satisfactory alter-
native medical pathway; can the patients obtain the test
from a different laboratory; can funds be raised for a rea-
sonable patent license; has the patent boosted follow-on
innovation such that there is net social beneﬁt?
Considered in the round, our view is that the results from
this study do not justify European patent law reform at
present. The 2017 expert review of the 98/44 EU Biotech
Directive reached a similar conclusion with respect to iso-
lated DNA sequence patents [42]. In our view, there is not
enough evidence of a problem, particularly given the rela-
tively low number of genetic tests affected. The US
experience also shows that law reform in this area is chal-
lenging [43], and, especially a decision like Mayo, is likely
to lead to undesirable uncertainty for those involved in
translational research on new molecular tests [44–46].
That said, our survey shows that the patent system is
likely to continue throwing up occasional problems as
innovation develops. Over time, the current crop of pro-
blematic patents will expire and others will probably take
their place. For instance, as the survey concluded, the
foundational patent for NIPT has expired, as has the patent
for FLT3. At any point in time there is likely to be a handful
of patents resulting in blocking, licensing disagreements, or
outsourcing of testing or research. European laboratories
and their patients deserve some sort of support to help deal
with these problems.
Conclusion and recommendations
To help European laboratories manage the increased burden
of gene-related patents, we recommend laboratories, parti-
cularly public sector laboratories, be given better IP legal
support. This survey shows that although the impact of
patents has increased in some respects, legal support has not
improved over the same time-frame. This is despite repeated
recommendations for better support over the past 15 years
[5, 47].
Among other things, improved legal support would help
laboratories: avoid high risks of patent infringement; iden-
tify ways to reduce the impact of patents (e.g., through
licensing or outsourcing); and notify laboratories when key
patents have expired or are no longer maintained in parti-
cular jurisdictions [48]. Useful general information could be
organised and disseminated through general public channels
(e.g., health departments, national patent ofﬁces, consultant
reports or academic publications). Ideally, improved legal
support would be tailored to speciﬁc organisations (e.g.,
university or research institute) and local conditions (e.g.,
country and tests offered). It is important that the advice is
smart and not overly cautious; many granted patents have
doubtful validity [49–52] and, in the right circumstances,
ignoring patents can be the best strategy. As the IP scholar,
Mark Lemley, notes: “[v]irtually everyone does it” [53].
Better IP support would enable laboratories to ignore
patents more strategically.
Further consideration could be given to centralised-
licensing of key patents by government bodies on behalf of
public hospitals that wish to use the patents. This might help
address concerns that stand-alone license fees are unrea-
sonable. Any such efforts, though, should be careful not to
delay unduly implementation of tests or lock laboratories
into tests that may become obsolete.
We also recommend watchful monitoring of gene-related
patent impacts. The trajectory over the past 10 years for
European laboratories is concerning, and there are signs that
negative impacts will continue, albeit ﬂuctuating, for some
time to come. For instance, our survey found that patent
owners tend to enforce patents against large or for-proﬁt
laboratories, meanwhile the survey also found marked
growth in these sectors of the industry. It is also signiﬁcant
that although the number of tests affected by gene-related
patents is currently small, one is a platform technology
(NIPT) with a multitude of applications. The primary
companies controlling the technology (Illumina and
Sequenom) [54], in part through their patent positions, have
strong market positions that could cause widespread issues
in the years ahead.
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